EDRS
TGTX icon

Edmond de Rothschild (Suisse)’s TG Therapeutics TGTX Stock Holding History

Edmond de Rothschild (Suisse)’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-443,400
Closed -$4.47M – 436
2015
Q3 		$4.47M Sell
443,400
-81,668
-16% -$1.22M 1.51% 12
2015
Q2 		$8.71M Buy
+525,068
New +$8.31M 2.76% 7

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Edmond de Rothschild (Suisse)'s TGTX Position: Q4 2015 in Review

Edmond de Rothschild (Suisse) sold out of TG Therapeutics (TGTX) in Q4 2015, closing a stake of 443,400 shares — an estimated $4.47M sold.

Edmond de Rothschild (Suisse) first reported a position in TGTX in Q2 2015 and held it in 2 quarters. The position peaked at $8.71M in Q2 2015. 87 funds tracked by Wall St. Rank hold TGTX as of Q4 2015.

  • Edmond de Rothschild (Suisse) reported no remaining TG Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Edmond de Rothschild (Suisse) sold 443,400 TG Therapeutics shares in Q4 2015, an estimated $4.47M.
  • Edmond de Rothschild (Suisse) first reported a position in TG Therapeutics in Q2 2015 and held it in 2 quarters.
  • Edmond de Rothschild (Suisse)'s TG Therapeutics position peaked at $8.71M in Q2 2015.
  • 87 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2015.

Based on Edmond de Rothschild (Suisse)'s 13F filing for Q4 2015, filed 16 Feb 2016.